HRNR and diffuse large B-cell lymphoma: After the initial promising data from these small trials, a larger international phase II, single-arm, open-label study of lenalidomide in 217 patients with biopsy-proven relapsed or refractory aggressive DLBCL, FLG3, TmL, or MCL was initiated (NHL-003).